Physician profile
John Timothy Dow
NPI 1386605491
$591.56
in general payments reported to CMS, 2019-2025
16 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.83 · 2021: $28.69 · 2022: $92.36 · 2023: $196 · 2024: $122 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $457.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $101.14 | 2022-2023 | Trelegy Ellipta |
| Pfizer INC. | $97.82 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $67.22 | 2022-2025 | Rexulti |
| Amgen INC. | $64.82 | 2023-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $63.59 | 2023-2025 | Farxiga, Breztri |
| Abbvie INC. | $25.20 | 2025 | |
| Dexcom, INC. | $22.57 | 2024 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $21.69 | 2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $21.62 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.51 | 2023 | |
| Mylan Specialty L.P. | $18.24 | 2023 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.42 | 2024 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.19 | 2024 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.04 | 2023 | Jardiance |
| Lundbeck LLC | $13.66 | 2024 | Rexulti |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $12.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.